ReviewBMC medicine2012

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Iakov N Rudenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.